TYROBP and tauopathy: The key observation in the current study is that phenotypic and pathophysiological symptoms and signs of tauopathy toxicity can be relieved when tauopathy model mice are constitutively deficient in a microglial-/dendritic cell-specific molecule (TYROBP), despite the fact that the severity of the tauopathy is not abated.